KeyBanc raised the firm’s price target on HCA Healthcare (HCA) to $550 from $500 and keeps an Overweight rating on the shares. The firm notes the company’s Q4 results were very solid, highlighted by a 2% EBITDA beat supported by strong core results and upside from Medicaid SDPs. More importantly, 2026 guidance of $16B came in well above the buyside bogie of $15.6B-$15.7B, underpinned by impressive efficiency initiatives and momentum with underlying EBITDA growth.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HCA:
- HCA Healthcare price target raised to $551 from $494 at Barclays
- HCA Healthcare Earnings Call: Growth Amid Policy Strain
- HCA Healthcare price target raised to $540 from $485 at BofA
- Early notable gainers among liquid option names on January 27th
- Morning Movers: Managed care group slide after CMS notice